rosiglitazone has been researched along with Metabolic Syndrome in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 55 (66.27) | 29.6817 |
| 2010's | 26 (31.33) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Brune, M; Bush, E; Chiou, W; Fung, S; Imade, H; Jacobson, P; Knourek-Segel, V; Kurukulasuriya, R; Link, JT; Monzon, K; Nguyen, PT; Shapiro, R; Stolarik, D; Wang, J; Wilcox, D; Yeh, VS | 1 |
| Audinot, V; Ayral, E; Boutin, JA; Caignard, DH; Caijo, F; Dacquet, C; Girard, AL; Grée, R; Ktorza, A; Liutkus, M; Mosset, P; Renard, P | 1 |
| Hiramoto, M; Hirao, A; Irii, H; Ishii, H; Okamoto, M; Shibata, S; Shimizu, I; Tahara, Y; Takanishi, A; Udagawa, H; Yasuda, K | 1 |
| Angioni, C; Blöcher, R; Boß, M; Brüggerhoff, A; Brüne, B; Diehl, O; Geisslinger, G; Göbel, T; Grundmann, M; Hartmann, M; Heering, J; Kahnt, AS; Kaiser, A; Kostenis, E; Lamers, C; Merk, D; Proschak, E; Schader, T; Schubert-Zsilavecz, M; Steinhilber, D; Weizel, L; Wittmann, SK; Wurglics, M | 1 |
| Huang, Z; Li, Y; Liu, J; Ma, W; Miranda, KM; Peng, S; Tian, J; Zhang, Y | 1 |
| Fenaux, M; Halcomb, RL; Jones, CT; Romero, FA; Xu, Y | 1 |
| Cai, Z; Han, J; Li, Z; Ren, Q; Wang, B; Zhang, L; Zhou, Z | 1 |
| Azhar, S; Bittner, S; Han, L; Kraemer, FB; Shen, WJ | 1 |
| den Hartigh, LJ; Goodspeed, L; Houston, B; Turk, KE; Wang, S | 1 |
| Huang, L; Weng, C; Xing, X; Yang, Y; Yuan, H | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Gandica, R; Zeitler, P | 1 |
| Andrisani, OM; Bi, P; Bidwell, CA; Castro, B; Durkes, A; Elzey, BD; Freeman, JL; Karki, A; Konieczny, SF; Kuang, S; Wang, C; Wirbisky, SE; Yue, F | 1 |
| Felson, S; Fisher, E; Schwartzbard, A; Zinn, A | 1 |
| Chalasani, N; Vuppalanchi, R | 1 |
| Ecelbarger, CM; Hu, J; Hu, X; Riazi, S; Tiwari, S; Wang, X | 1 |
| Borba, CP; Boxill, R; Cather, C; Copeland, PM; Eden Evins, A; Fan, X; Freudenreich, O; Goff, DC; Henderson, DC; Sharma, B | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Argo, TR; Housel, AK; Waterbury, N | 1 |
| Aukrust, P; Damås, JK; Halvorsen, B; Heggen, E; Otterdal, K; Sandberg, WJ; Smith, C; Tonstad, S; Ueland, T | 1 |
| Dzanković, F; Macić-Dzanković, A; Pojskić, B; Velija-Asimi, Z | 1 |
| Boerman, OC; Meijer, P; Oyen, WJ; Rennings, AJ; Rongen, GA; Smits, P; Tack, CJ; van Uden, DJ | 1 |
| Bahia, LR; Bouskela, E; Domingues, RC; Geloneze, B; Godoy-Matos, AF; Kraemer-Aguiar, LG; Tambascia, M | 1 |
| Aquilante, CL; Knutsen, SD; Kosmiski, LA; Rome, LC; Zineh, I | 1 |
| Ackerman, Z; Grozovski, M; Oron-Herman, M; Pappo, O; Peleg, E; Safadi, R; Schmilovitz-Weiss, H | 1 |
| Baxter, JD; Collins, AR; Finegold, MJ; Gupte, AA; Hsueh, WA; Liu, JZ; Lyon, CJ; Minze, LJ; Moore, DD; Pratico, D; Ren, Y; Webb, P; Wiles, JR; Wong, ST | 1 |
| Bloedon, LT; Ikewaki, K; Millar, JS; Rader, DJ; Szapary, PO; Wolfe, ML | 1 |
| Chen, W; Liu, HY; Wang, LL; Zhang, LH; Zhou, XB | 1 |
| Bastacky, S; Bilan, VP; Jones, HB; Mayers, RM; Poucher, SM; Salah, EM; Tofovic, SP; Zinker, B | 1 |
| Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Bakris, G; de Guzman, E; Lazich, I; Oliva, R; Patel, A; Sarafidis, P | 1 |
| Kamal, MA; Qu, X; Seale, JP; Sun, LQ; Tan, Y; Wang, X | 1 |
| de Roos, A; Dehnavi, RA; Lamb, HJ; Mertens, BJ; Roes, SD; Tamsma, JT; Westenberg, JJ | 1 |
| Aimo, L; Berryhill, GE; Cardiff, RD; Gloviczki, JM; Hovey, RC; Kraft, J; Lock, AL; Paul, CT; Petrie, WK; Trott, JF | 1 |
| Harini, R; Pugalendi, KV; Sundaresan, A | 1 |
| Muthulakshmi, S; Saravanan, R | 1 |
| Kazdová, L; Kren, V; Krenová, D; Seda, O | 1 |
| Acerini, CL; Agostini, M; Bell, JD; Boiani, R; Chatterjee, VK; Cinti, S; Dixon, AK; Dunne, F; Gurnell, M; Jebb, SA; Karpe, F; O'Rahilly, S; Savage, DB; Tan, GD; Thomas, EL; Umpleby, AM; Vidal-Puig, A; Williams, RL | 1 |
| Henry, RR | 1 |
| Barak, Y; Evans, RM; He, W; Hevener, A; Le, J; Liao, D; Nelson, M; Olefsky, JM; Olson, P; Ong, E | 1 |
| Chen, MF; Chen, WJ; Lee, YT; Lin, JW; Wang, TD | 1 |
| Moyle, G; Sutinen, J | 1 |
| Roden, M; Stingl, H | 1 |
| Bertone, G; Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Gaddi, A; Piccinni, MN; Ragonesi, PD | 1 |
| Füchtenbusch, M; Löbner, K | 1 |
| Hegele, RA | 1 |
| Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Gaddi, AV; Ghelfi, M; Peros, E; Piccinni, MN; Salvadeo, S | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Fogari, E; Fogari, R; Gaddi, A; Piccinni, MN; Ragonesi, PD; Salvadeo, S | 1 |
| Moreno Sánchez, D | 1 |
| Ciccarelli, L; Cicero, AF; Derosa, G; Ferrari, I; Fogari, E; Fogari, R; Gaddi, AV; Ghelfi, M; Piccinni, MN; Pricolo, F; Salvadeo, S | 1 |
| Abbasi, F; Chu, JW; Lamendola, C; McLaughlin, T; Reaven, GM; Tsao, PS | 1 |
| Adler, S; Banz, WJ; Davis, J; Henry, N; Higginbotham, DA; Hou, Y; Meyers, CY; Oitker, J; Peterson, R; Steinle, JJ; Winters, TA | 1 |
| Bloedon, LT; Iqbal, N; Kochar, A; Rader, DJ; Samaha, FF; Szapary, PO; Williams, MM; Wolfe, ML | 1 |
| Baik, SH; Choi, DS; Choi, KM; Kim, HY; Kim, NH; Kim, SG; Lee, J; Lee, KW; Ryu, OH; Seo, JA | 1 |
| Rennings, AJ; Smits, P; Stewart, MW; Tack, CJ | 1 |
| Esposito, K; Giugliano, D | 1 |
| Assaloni, R; Carleo, D; Ceriello, A; Ciotola, M; Cozzolino, D; Esposito, K; Giugliano, D; Merante, D; Saccomanno, F; Sasso, FC; Schisano, B | 1 |
| Ciotola, M; Esposito, K; Giugliano, D; Merante, D | 1 |
| Aguiar, LG; Bahia, L; Bottino, D; Bouskela, E; Godoy-Matos, AF; Villela, N | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gaddi, A; Gravina, A; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 1 |
| Cao, Z; Cheng, WJ; Guo, YH; Liu, YY; Zhao, YX; Zhou, YJ | 1 |
| Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Montagna, L; Paniga, S; Piccinni, MN; Pricolo, F; Ragonesi, PD; Salvadeo, SA | 2 |
| Chen, MF; Chen, WJ; Cheng, WC; Lee, YT; Lin, JW; Wang, TD | 1 |
| Aguiar, LG; Bahia, L; Bottino, D; Bouskela, E; Geloneze, B; Godoy-Matos, AF; Tambascia, M; Villela, N | 1 |
| Freed, MI; Haffner, S; Heise, MA; Herman, WH; Holman, R; Jones, NP; Kahn, SE; Kravitz, B; Lachin, J; O'Neill, MC; Viberti, G; Zinman, B | 1 |
| Avni, I; Grossman, E; Kamari, Y; Oron-Herman, M; Peleg, E; Shabtay, Z; Shamiss, A; Sharabi, Y | 1 |
| Adler, S; Banz, W; Cho, KW; Davis, J; Higginbotham, A; Kim, YC; Moustaid-Moussa, N; O'Connor, T; Peterson, R; Shay, N; Tebbe, A | 1 |
| Beaser, RS; Levy, P | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Fassi, R; Ferrari, I; Fogari, E; Fogari, R; Gravina, A; Ragonesi, PD; Salvadeo, SA | 1 |
| Abdel-Latif, A; AlMahameed, A; Bhatt, DL; Blankenship, JC; Brennan, D; Chew, DP; Corbelli, JC; Eres, A; Gilchrist, IC; Grines, C; Hazen, SL; Leesar, M; McErlean, E; Mukherjee, D; Resar, JR; Steinhubl, S; Tan, WA; Tang, HW; Tang, WH; Topol, EJ | 1 |
| Buettner, J; Lüdtke, A; Schmidt, HH; Worman, HJ | 1 |
| Chalasani, N; Khashab, M | 1 |
| Javashvili, L; Kilasonia, L; Tananashvili, D; Tetradze, L; Virsaladze, D | 1 |
| Bahia, LR; Bottino, DA; Bouskela, E; Kraemer de Aguiar, LG; Nivoit, P; Villela, NR | 1 |
| Carson, S; Norris, SL; Roberts, C | 1 |
| Corbeil, G; Hamet, P; Kazdová, L; Kren, V; Krenová, D; Oliyarnyk, O; Seda, O; Sedová, L; Tremblay, J | 1 |
| Chillarón, JJ; Goday, A; Pedro-Botet, J | 1 |
| Csermely, P; Jermendy, G | 1 |
| Hsueh, WA; Law, RE | 1 |
| Abbasi, F; Chu, JW; Cooke, JP; Lamendola, C; McLaughlin, TL; Reaven, GM; Stühlinger, MC; Tsao, PS | 1 |
| Ardecky, RJ; Bean, JS; Bensch, WR; Bilakovics, JM; Broderick, CL; Brooks, DA; Brozinick, JT; Dana, SL; Etgen, GJ; Johnson, WT; Kauffman, RF; Liu, S; McCarthy, JR; Misener, EA; Montrose, CR; Ogilvie, KM; Oldham, BA; Paterniti, JR; Rito, CJ; Shuker, AJ; Tyhonas, JS | 1 |
15 review(s) available for rosiglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.
Topics: Animals; Anticholesteremic Agents; Drug Delivery Systems; Drug Development; Humans; Hypoglycemic Agents; Lipid Metabolism; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; PPAR gamma; Protein Structure, Tertiary | 2020 |
PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Pioglitazone; PPAR delta; PPAR gamma; PPAR-beta; Rosiglitazone; Thiazolidinediones | 2017 |
Update on Youth-Onset Type 2 Diabetes: Lessons Learned from the Treatment Options for Type 2 Diabetes in Adolescents and Youth Clinical Trial.
Topics: Adolescent; Child; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Pregnancy; Pregnancy Complications; Prenatal Exposure Delayed Effects; Rosiglitazone; Thiazolidinediones | 2016 |
Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Pioglitazone; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2008 |
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management.
Topics: Bariatric Surgery; Biomarkers; Biopsy; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Exercise; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Liver Diseases; Metabolic Syndrome; Metformin; Obesity; Oxidative Stress; Pioglitazone; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Weight Loss | 2009 |
Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
Topics: Antipsychotic Agents; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Randomized Controlled Trials as Topic; Risk Factors; Rosiglitazone; Schizophrenia; Thiazolidinediones; Weight Gain | 2009 |
Insulin resistance: from predisposing factor to therapeutic target in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
[Future targets in the treatment of type 2 diabetes].
Topics: Animals; Clinical Trials as Topic; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; Forecasting; Glucagon; Glucagon-Like Peptide 1; Glucose; Glycated Hemoglobin; Glycogen Synthase Kinase 3; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Peroxidation; Metabolic Syndrome; Mice; Oxazines; Peptide Fragments; Phenylpropionates; Protein Precursors; Rats; Receptor, Insulin; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Signal Transduction; Thiazolidinediones; Transcription Factors | 2004 |
[Inflammation and diabetes].
Topics: Adiponectin; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Blood Glucose; Body Weight; C-Reactive Protein; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Exercise; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Metabolic Syndrome; Obesity; Research; Risk Factors; Rosiglitazone; Thiazolidinediones | 2004 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Pioglitazone; Prognosis; Rosiglitazone; Thiazolidinediones; Troglitazone | 2007 |
Comparative effectiveness of pioglitazone and rosiglitazone in type 2 diabetes, prediabetes, and the metabolic syndrome: a meta-analysis.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Prediabetic State; Randomized Controlled Trials as Topic; Rosiglitazone; Thiazolidinediones; Treatment Outcome | 2007 |
[Metabolic syndrome, type 1 diabetes mellitus and insulin resistance].
Topics: Blood Glucose; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metabolic Syndrome; Rosiglitazone; Thiazolidinediones | 2008 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Troglitazone | 2001 |
PPARgamma and atherosclerosis: effects on cell growth and movement.
Topics: Animals; Arteriosclerosis; Cell Division; Cell Movement; Endothelium, Vascular; Humans; Metabolic Syndrome; Muscle, Smooth, Vascular; Pioglitazone; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2001 |
27 trial(s) available for rosiglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol, LDL; Clozapine; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Placebos; Rosiglitazone; Schizophrenia; Thiazolidinediones | 2009 |
Treatment with the PPARgamma agonist rosiglitazone downregulates interleukin-1 receptor antagonist in individuals with metabolic syndrome.
Topics: Adult; Aged; Biomarkers; Cross-Over Studies; Down-Regulation; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Inflammation; Interleukin 1 Receptor Antagonist Protein; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2010 |
Evaluation of risk markers fluctuation during an initial therapy with rosiglitazon in patients suffering from metabolic syndrome.
Topics: Biomarkers; C-Reactive Protein; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Longitudinal Studies; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Uric Acid | 2009 |
Rosiglitazone reduces ischaemia-reperfusion injury in patients with the metabolic syndrome.
Topics: Double-Blind Method; Forearm; Humans; Insulin Resistance; Ischemia; Metabolic Syndrome; Muscle, Skeletal; Radionuclide Imaging; Reperfusion Injury; Rosiglitazone; Thiazolidinediones; Vasodilator Agents | 2010 |
Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
Topics: Adiponectin; Adult; Biomarkers; Blood Glucose; Blood Pressure; Body Weight; Cardiovascular Diseases; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Resistin; Rosiglitazone; Thiazolidinediones; Time Factors; Waist Circumference | 2010 |
Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.
Topics: Adolescent; Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; C-Reactive Protein; Cholesterol, HDL; Humans; Insulin; Lipoproteins, HDL; Male; Metabolic Syndrome; Middle Aged; Rosiglitazone; Thiazolidinediones | 2011 |
Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
Topics: Adiponectin; Adult; Aged; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Coronary Artery Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Inflammation; Isoprostanes; Lipids; Male; Malondialdehyde; Metabolic Syndrome; Middle Aged; Oxidative Stress; Rosiglitazone; Simvastatin; Thiazolidinediones | 2012 |
Effect of lifestyle intervention plus rosiglitazone or placebo therapy on left ventricular mass assessed with cardiovascular magnetic resonance in the metabolic syndrome.
Topics: Aged; Combined Modality Therapy; Diet; Double-Blind Method; Exercise; Heart Ventricles; Humans; Hypertrophy, Left Ventricular; Hypoglycemic Agents; Linear Models; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Netherlands; Predictive Value of Tests; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Time Factors; Treatment Outcome; Ventricular Remodeling | 2011 |
Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
Topics: Adult; Aged; Brachial Artery; C-Reactive Protein; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Rosiglitazone; Thiazolidinediones; Vasodilation | 2004 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Topics: Adult; Aged; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2004 |
Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinogen; Fibrinolytic Agents; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Tissue Plasminogen Activator | 2005 |
A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndrome.
Topics: Aged; Blood Pressure; Body Size; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Postprandial Period; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triglycerides | 2005 |
Long-term effects of glimepiride or rosiglitazone in combination with metformin on blood pressure control in type 2 diabetic patients affected by the metabolic syndrome: a 12-month, double-blind, randomized clinical trial.
Topics: Analysis of Variance; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Time Factors | 2005 |
Effect of rosiglitazone treatment on circulating vascular and inflammatory markers in insulin-resistant subjects.
Topics: Anti-Inflammatory Agents; Blood Glucose; C-Reactive Protein; Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Inflammation; Inflammation Mediators; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Plasminogen Activator Inhibitor 1; Rosiglitazone; Selectins; Thiazolidinediones | 2005 |
Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
Topics: Adiponectin; Adolescent; Adult; Aged; Apolipoproteins B; Biomarkers; Blood Pressure; Body Weight; C-Reactive Protein; Cholesterol, HDL; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Receptors, Tumor Necrosis Factor, Type II; Resistin; Rosiglitazone; Thiazolidinediones | 2006 |
Effect of rosiglitazone on plasma adiponectin levels and arterial stiffness in subjects with prediabetes or non-diabetic metabolic syndrome.
Topics: Adiponectin; Adult; Aged; Anthropometry; Arteries; Brachial Artery; C-Reactive Protein; Cytokines; Female; Glucose Tolerance Test; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Prediabetic State; Resistin; Rosiglitazone; Thiazolidinediones | 2006 |
Fluid retention and vascular effects of rosiglitazone in obese, insulin-resistant, nondiabetic subjects.
Topics: Adult; Blood Pressure; Capillary Permeability; Edema; Female; Forearm; Humans; Insulin; Insulin Resistance; Male; Metabolic Syndrome; Middle Aged; Obesity; omega-N-Methylarginine; Plasma Volume; Regional Blood Flow; Rosiglitazone; Thiazolidinediones; Vasodilation | 2006 |
Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
Topics: Adult; Blood Glucose; Blood Pressure; Body Size; Double-Blind Method; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Inflammation; Insulin; Lipids; Male; Metabolic Syndrome; Middle Aged; Rosiglitazone; Thiazolidinediones | 2006 |
Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled
Topics: Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocystine; Humans; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Pioglitazone; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones | 2006 |
Rosiglitazone could improve clinical outcomes after coronary stent implantation in nondiabetic patients with metabolic syndrome.
Topics: Aged; Angioplasty, Balloon, Coronary; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Rosiglitazone; Stents; Thiazolidinediones | 2006 |
Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Homocysteine; Humans; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2006 |
Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
Topics: Arginine; Blood Pressure; Body Mass Index; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Endothelin-1; Endothelium-Dependent Relaxing Factors; Female; Glucose; Humans; Insulin; Male; Metabolic Syndrome; Middle Aged; Regression Analysis; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2006 |
A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe.
Topics: Adult; Age Distribution; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Glyburide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Metformin; Middle Aged; North America; Racial Groups; Rosiglitazone; Sex Distribution; Thiazolidinediones | 2006 |
Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
Topics: Aged; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Metabolic Syndrome; Metformin; Middle Aged; Pioglitazone; Rosiglitazone; Thiazolidinediones | 2007 |
Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Topics: Adiponectin; Administration, Oral; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Glucose; Blood Pressure; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Irbesartan; Lipids; Male; Metabolic Syndrome; Resistin; Rosiglitazone; Telmisartan; Tetrazoles; Thiazolidinediones; Treatment Outcome | 2007 |
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study.
Topics: Angioplasty, Balloon, Coronary; Biomarkers; Cardiovascular Diseases; Coronary Disease; Disease Progression; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Middle Aged; Natriuretic Peptide, Brain; Pilot Projects; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
[Relation of serum uric acid levels with basic metabolic parameters in patients with metabolic syndrome during insulin-sensitizing therapy].
Topics: Adult; Female; Humans; Hypoglycemic Agents; Male; Metabolic Syndrome; Metformin; Rosiglitazone; Thiazolidinediones; Uric Acid | 2007 |
41 other study(ies) available for rosiglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Administration, Oral; Animals; Humans; Lactams; Metabolic Syndrome; Mice | 2006 |
Synthesis of new 8(S)-HETE analogs and their biological evaluation as activators of the PPAR nuclear receptors.
Topics: Animals; Caprylates; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Genes, Reporter; Humans; Hydroxyeicosatetraenoic Acids; Hypoglycemic Agents; Kinetics; Metabolic Syndrome; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Quinolines; Recombinant Fusion Proteins; Structure-Activity Relationship; Transcriptional Activation | 2010 |
Synthesis of a new [6]-gingerol analogue and its protective effect with respect to the development of metabolic syndrome in mice fed a high-fat diet.
Topics: Acetyl-CoA Carboxylase; Adiponectin; Adipose Tissue; Amides; Animals; Anti-Obesity Agents; Blood Glucose; Body Weight; Catechols; Dietary Fats; Energy Metabolism; Fatty Alcohols; Glucose Tolerance Test; Guaiacol; Insulin; Leptin; Lipogenesis; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Sterol Regulatory Element Binding Protein 1 | 2011 |
N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
Topics: 3T3 Cells; Administration, Oral; Animals; Benzamides; Chlorocebus aethiops; COS Cells; Diabetes Mellitus, Type 2; Drug Design; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Hypertension; In Vitro Techniques; Metabolic Syndrome; Mice; Microsomes, Liver; PPAR gamma; Rats; Structure-Activity Relationship | 2016 |
Design and synthesis of rosiglitazone-ferulic acid-nitric oxide donor trihybrids for improving glucose tolerance.
Topics: Anti-Inflammatory Agents; Antioxidants; Aquaporin 2; Cells, Cultured; Coumaric Acids; Diabetes Mellitus, Type 2; Drug Design; Glucose Intolerance; Humans; Kidney Tubules, Collecting; Metabolic Syndrome; Microsomes, Liver; Nitric Oxide Donors; Rosiglitazone | 2019 |
Discovery of the first-in-class dual PPARδ/γ partial agonist for the treatment of metabolic syndrome.
Topics: Animals; Diabetes Mellitus, Experimental; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Discovery; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Molecular Structure; Organic Chemicals; PPAR delta; PPAR gamma; Rats; Rats, Sprague-Dawley; Streptozocin; Structure-Activity Relationship | 2021 |
Rosiglitazone Improves Insulin Resistance Mediated by 10,12 Conjugated Linoleic Acid in a Male Mouse Model of Metabolic Syndrome.
Topics: 3T3-L1 Cells; Adipose Tissue; Animals; Body Weight; Disease Models, Animal; Glucose; Insulin Resistance; Linoleic Acids, Conjugated; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Mice, Knockout; Obesity; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2017 |
Resistin, an adipokine, may affect the improvement of insulin sensitivity in the metabolic syndrome patient treated with metformin.
Topics: Humans; Insulin Resistance; Metabolic Syndrome; Metformin; Models, Biological; Resistin; Rosiglitazone; Thiazolidinediones | 2013 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Notch activation drives adipocyte dedifferentiation and tumorigenic transformation in mice.
Topics: Adipocytes; Animals; Biomarkers, Tumor; Cell Dedifferentiation; Cell Differentiation; Cell Lineage; Cell Proliferation; Cell Transformation, Neoplastic; Diabetes Mellitus, Experimental; Diamines; Dibenzazepines; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Ligands; Lipid Metabolism; Liposarcoma; Metabolic Syndrome; Mice, Inbred C57BL; PPAR gamma; Precancerous Conditions; PTEN Phosphohydrolase; Receptors, Notch; Rosiglitazone; Signal Transduction; Thiazoles; Thiazolidinediones; Xenograft Model Antitumor Assays | 2016 |
Regulation of angiotensin II type I receptor (AT1R) protein levels in the obese Zucker rat kidney and urine.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Biomarkers; Biphenyl Compounds; Blood Pressure; Disease Models, Animal; Humans; Hypertension; Hypoglycemic Agents; Kidney; Metabolic Syndrome; Obesity; PPAR gamma; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Rosiglitazone; Sodium Chloride, Dietary; Tetrazoles; Thiazolidinediones; Thinness | 2009 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Rosiglitazone decreases intra- to extramyocellular fat ratio in obese non-diabetic adults with metabolic syndrome.
Topics: Adipose Tissue; Adult; Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Magnetic Resonance Spectroscopy; Male; Metabolic Syndrome; Obesity; Rosiglitazone; Thiazolidinediones; Triglycerides; Waist-Hip Ratio | 2010 |
Hepatic effects of rosiglitazone in rats with the metabolic syndrome.
Topics: Adiponectin; alpha-Tocopherol; Animal Feed; Animals; Aryldialkylphosphatase; Blood Pressure; Fatty Liver; Fructose; Glutathione Reductase; Hypoglycemic Agents; Lipid Metabolism; Lipids; Liver; Liver Cirrhosis; Male; Malondialdehyde; Metabolic Syndrome; Phospholipids; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone attenuates age- and diet-associated nonalcoholic steatohepatitis in male low-density lipoprotein receptor knockout mice.
Topics: Aging; Animals; Antioxidants; Dietary Fats; Fatty Liver; Gene Expression; Hepatitis; Liver; Male; Metabolic Syndrome; Mice; Mice, Knockout; Mitochondria, Liver; Oxidative Stress; PPAR gamma; Receptors, LDL; Rosiglitazone; Thiazolidinediones | 2010 |
Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue, White; Animals; Animals, Newborn; Blood Glucose; Body Weight; Drug Synergism; Eating; Fenofibrate; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lipids; Lipoprotein Lipase; Liver; Metabolic Syndrome; Mice; Mice, Inbred ICR; RNA, Messenger; Rosiglitazone; Sodium Glutamate; Thiazolidinediones | 2010 |
Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Diabetic Nephropathies; Disease Models, Animal; Enalapril; Humans; Hypoglycemic Agents; Kidney; Liver; Male; Metabolic Syndrome; Myocardium; Obesity; PPAR gamma; Rats; Rosiglitazone; Thiazolidinediones | 2011 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones | 2011 |
Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and non-alcoholic fatty liver disease in mice.
Topics: 3T3-L1 Cells; Adipocytes; Adipose Tissue; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Diet, High-Fat; Fatty Liver; Glucose Transporter Type 4; Insulin; Insulin Resistance; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Oligonucleotides, Antisense; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones; Transfection | 2011 |
Diet-induced metabolic change induces estrogen-independent allometric mammary growth.
Topics: Animal Feed; Animals; Blotting, Western; Corticosterone; DNA Primers; Fatty Acids; Female; Histological Techniques; Insulin; Insulin-Like Growth Factor I; Least-Squares Analysis; Linoleic Acids, Conjugated; Mammary Glands, Animal; Metabolic Syndrome; Mice; Mice, Inbred BALB C; Mice, Transgenic; Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones | 2012 |
Ursolic acid and rosiglitazone combination alleviates metabolic syndrome in high fat diet fed C57BL/6J mice.
Topics: Animals; Body Weight; Cyclooxygenase Inhibitors; Dietary Fats; Drug Therapy, Combination; Hypoglycemic Agents; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Triterpenes; Ursolic Acid | 2012 |
Protective effects of azelaic acid against high-fat diet-induced oxidative stress in liver, kidney and heart of C57BL/6J mice.
Topics: Animals; Antioxidants; Ascorbic Acid; Biomarkers; Blood Glucose; Body Weight; Dicarboxylic Acids; Diet, High-Fat; Eating; Erythrocytes; Glutathione; Glutathione Peroxidase; Glutathione Transferase; Heart; Hypoglycemic Agents; Insulin; Kidney; Liver; Male; Metabolic Syndrome; Mice; Mice, Inbred C57BL; Myocardium; Oxidative Stress; Rosiglitazone; Thiazolidinediones; Thiobarbituric Acid Reactive Substances; Triglycerides; Vitamin E | 2013 |
Rosiglitazone improves insulin resistance, lipid profile and promotes adiposity in a genetic model of metabolic syndrome X.
Topics: Adipose Tissue; Animals; Disease Models, Animal; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Male; Metabolic Syndrome; Rats; Rats, Inbred Strains; Rosiglitazone; Thiazoles; Thiazolidinediones | 2002 |
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Carrier Proteins; Fatty Acid-Binding Protein 7; Fatty Acid-Binding Proteins; Fatty Acids; Fatty Acids, Nonesterified; Fatty Liver; Female; Gene Expression; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Liver; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Middle Aged; Mutation; Neoplasm Proteins; Phenotype; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Triglycerides; Tumor Suppressor Proteins | 2003 |
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Animals; Hypoglycemic Agents; Insulin Resistance; Intercellular Signaling Peptides and Proteins; Leptin; Lipodystrophy; Liver; Liver Function Tests; Metabolic Syndrome; Mice; Mice, Knockout; Muscle, Skeletal; Organ Specificity; Proteins; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors | 2003 |
Managing HIV lipoatrophy.
Topics: Anti-HIV Agents; Dideoxynucleosides; HIV-Associated Lipodystrophy Syndrome; Human Growth Hormone; Humans; Hypoglycemic Agents; Metabolic Syndrome; Protease Inhibitors; Randomized Controlled Trials as Topic; Recombinant Proteins; Reverse Transcriptase Inhibitors; Rosiglitazone; Stavudine; Thiazolidinediones; Treatment Outcome | 2004 |
Lessons from human mutations in PPARgamma.
Topics: Adult; Female; Germ-Line Mutation; Humans; Hypoglycemic Agents; Insulin Resistance; Lipodystrophy; Male; Metabolic Syndrome; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2005 |
Risk reduction therapy for syndrome X: comparison of several treatments.
Topics: Amlodipine; Animals; Antihypertensive Agents; Bezafibrate; Blood Pressure; Body Weight; Captopril; Fructose; Hydrolases; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Insulin; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley; Risk Reduction Behavior; Rosiglitazone; Thiazolidinediones; Triglycerides | 2005 |
(+)-Z-Bisdehydrodoisynolic acid ameliorates obesity and the metabolic syndrome in female ZDF rats.
Topics: Animals; Blood Glucose; Body Weight; Cholesterol; Coronary Vessels; Diabetes Mellitus, Experimental; Disease Models, Animal; Female; Gene Expression; Hypoglycemic Agents; Kidney; Liver; Metabolic Syndrome; Obesity; Organ Size; Phenanthrenes; PPAR alpha; PPAR gamma; Random Allocation; Rats; Rats, Zucker; Risk Factors; Rosiglitazone; Selective Estrogen Receptor Modulators; Thiazolidinediones; Triglycerides | 2005 |
Optimal treatments for the metabolic syndrome.
Topics: Anti-Obesity Agents; Cardiovascular Diseases; Complementary Therapies; Diabetes Mellitus; Diet; Health Behavior; Humans; Hypoglycemic Agents; Life Style; Metabolic Syndrome; Metformin; Obesity; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Rosiglitazone; Thiazolidinediones | 2006 |
Rosiglitazone cools down inflammation in the metabolic syndrome.
Topics: Adult; Female; Humans; Inflammation; Male; Metabolic Syndrome; Middle Aged; Rosiglitazone; Severity of Illness Index; Thiazolidinediones | 2006 |
[Effects of rosiglitazone on endothelial function in non-diabetic subjects with metabolic syndrome].
Topics: Adult; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Inflammation; Male; Metabolic Syndrome; Risk Factors; Rosiglitazone; Thiazolidinediones; Vasodilation; Vasodilator Agents | 2006 |
Adiponectin is associated with improvement of endothelial function after rosiglitazone treatment in non-diabetic individuals with metabolic syndrome.
Topics: Acetylcholine; Adiponectin; Adult; C-Reactive Protein; Endothelium, Vascular; Female; Glucose Tolerance Test; Humans; Hypertension; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Middle Aged; Nitroprusside; Rosiglitazone; Thiazolidinediones | 2007 |
Effect of PPAR-gamma agonist on adiponectin levels in the metabolic syndrome: lessons from the high fructose fed rat model.
Topics: Adiponectin; Adipose Tissue; Animals; Blood Pressure; Diet; Disease Models, Animal; Fructose; Glucose Tolerance Test; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; PPAR gamma; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Triglycerides; Up-Regulation | 2007 |
Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat.
Topics: Adiposity; Animals; Blood Glucose; Caseins; Hypoglycemic Agents; Isoflavones; Kidney Diseases; Liver; Male; Metabolic Syndrome; Milk Proteins; Obesity; Proteinuria; Rats; Rats, Inbred Strains; Rosiglitazone; Soybean Proteins; Thiazolidinediones | 2007 |
Metabolic syndrome: a work in progress, but a useful construct.
Topics: Abdominal Fat; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Metabolic Syndrome; Models, Biological; Obesity; Prognosis; Risk Factors; Rosiglitazone; Thiazolidinediones | 2007 |
New PPARG mutation leads to lipodystrophy and loss of protein function that is partially restored by a synthetic ligand.
Topics: Adolescent; Adult; Amino Acid Substitution; Animals; Cell Line; Female; Genes, Reporter; Humans; Lipodystrophy, Familial Partial; Metabolic Syndrome; Mutation, Missense; Pedigree; Point Mutation; PPAR gamma; Protein Structure, Tertiary; Rosiglitazone; Thiazolidinediones; Transcription, Genetic; Transfection | 2007 |
[Vascular dysfunction in metabolic disorders: evaluation of some therapeutic interventions].
Topics: Adolescent; Adult; Capillary Permeability; Case-Control Studies; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hypoglycemic Agents; Metabolic Syndrome; Metformin; Microcirculation; Microscopic Angioscopy; Obesity; Plethysmography; Rosiglitazone; Thiazolidinediones; Treatment Outcome; Vasodilator Agents | 2007 |
Pharmacogenomics of metabolic effects of rosiglitazone.
Topics: Adipose Tissue; Adipose Tissue, White; Animals; Cholesterol, Dietary; Diet; Dietary Carbohydrates; Fatty Acids; Gene Expression; Glucose; Glucose Tolerance Test; Glycogen; Hypoglycemic Agents; Insulin Resistance; Lipids; Liver; Metabolic Syndrome; Microarray Analysis; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Inbred BN; Rats, Inbred Strains; RNA; Rosiglitazone; Sucrose; Thiazolidinediones | 2008 |
Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor.
Topics: Adult; Aged; Arginine; Cardiovascular Diseases; Cross-Sectional Studies; Enzyme Inhibitors; Female; Humans; Hypertension; Hypoglycemic Agents; Lipoproteins; Male; Metabolic Diseases; Metabolic Syndrome; Middle Aged; Nitric Oxide Synthase; Regression Analysis; Risk Factors; Rosiglitazone; Thiazoles; Thiazolidinediones; Vasodilator Agents | 2002 |
A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Dose-Response Relationship, Drug; Energy Intake; Energy Metabolism; Glucose Tolerance Test; Hyperglycemia; Hypoglycemic Agents; Insulin Resistance; Male; Metabolic Syndrome; Mice; Mice, Mutant Strains; Organic Chemicals; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors | 2002 |